Details of the Drug

General Information of Drug (ID: DMVXFYE)

Drug Name
Vinorelbine
Synonyms
Eunades; Exelbine; NVB; Navelbine; Vinorelbin; Vinorelbina; Vinorelbinum; Navelbine base; Vinorelbina [Spanish]; Vinorelbine Ditartarate; Vinorelbine ditartrate; Vinorelbine tartrate; Vinorelbinum [Latin]; KW 2307; KW 2307 base; ANX-530; KW-2307; Navelbine (TN); SDP-012; Vinorelbine (INN); Vinorelbine [INN:BAN]; Aspidospermidine-3-carboxylic acid; Nor-5'-anhydrovinblastine; Methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate; Methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 778.9
Topological Polar Surface Area (xlogp) 3.6
Rotatable Bond Count (rotbonds) 10
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 11
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 20 mL/min/kg [4]
Elimination
Urinary excretion of unchanged drug accounts for less than 20% of an intravenous dose, with fecal elimination accounting for an additional 30% to 60% [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 27.7 - 43.6 hours [6]
Metabolism
The drug is metabolized via the hepatic [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.87% [4]
Vd
The volume of distribution (Vd) of drug is 25.4-40.1 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 1000 mg/mL [3]
Chemical Identifiers
Formula
C45H54N4O8
IUPAC Name
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
Canonical SMILES
CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
InChI
InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45-/m0/s1
InChIKey
GBABOYUKABKIAF-IELIFDKJSA-N
Cross-matching ID
PubChem CID
5311497
ChEBI ID
CHEBI:480999
CAS Number
71486-22-1
DrugBank ID
DB00361
TTD ID
D01HTL
VARIDT ID
DR01343
INTEDE ID
DR1696

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tubulin (TUB) DTT NO-GeName 7.94E-02 0.35 0.43
P-glycoprotein 1 (ABCB1) DTP P-GP 1.53E-04 -6.93E-01 -2.04E+00
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 1.02E-01 -3.26E-02 -1.33E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 2.96E-01 -3.35E-01 -1.10E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vinorelbine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Vinorelbine caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Armodafinil DMGB035 Minor Increased metabolism of Vinorelbine caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
LEE011 DMMX75K Moderate Decreased metabolism of Vinorelbine caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [45]
Coadministration of a Drug Treating the Disease Different from Vinorelbine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Vinorelbine caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [46]
Midostaurin DMI6E0R Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [47]
Arn-509 DMT81LZ Moderate Accelerated clearance of Vinorelbine due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [47]
Gilteritinib DMWQ4MZ Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [43]
Siltuximab DMGEATB Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Siltuximab. Anemia [3A00-3A9Z] [47]
Dronedarone DMA8FS5 Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [48]
Voriconazole DMAOL2S Major Decreased clearance of Vinorelbine due to the transporter inhibition by Voriconazole. Aspergillosis [1F20] [49]
Posaconazole DMUL5EW Major Decreased metabolism of Vinorelbine caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [49]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Roflumilast. Asthma [CA23] [47]
Ofloxacin DM0VQN3 Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [50]
Ciprofloxacin XR DM2NLS9 Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [50]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Vinorelbine caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [51]
Clarithromycin DM4M1SG Major Decreased metabolism of Vinorelbine caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [49]
Trovafloxacin DM6AN32 Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [50]
Sparfloxacin DMB4HCT Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [50]
Gemifloxacin DMHT34O Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [50]
Norfloxacin DMIZ6W2 Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [50]
ABT-492 DMJFD2I Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [50]
Levofloxacin DMS60RB Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [50]
Troleandomycin DMUZNIG Major Decreased clearance of Vinorelbine due to the transporter inhibition by Troleandomycin. Bacterial infection [1A00-1C4Z] [49]
Lomefloxacin DMVRH9C Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [50]
Telithromycin DMZ4P3A Major Decreased metabolism of Vinorelbine caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [49]
Erdafitinib DMI782S Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [52]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Vinorelbine caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [53]
Tucatinib DMBESUA Major Decreased clearance of Vinorelbine due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [49]
Palbociclib DMD7L94 Moderate Decreased metabolism of Vinorelbine caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Grepafloxacin DMGLX0T Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Grepafloxacin. Bronchitis [CA20] [50]
Secobarbital DM14RF5 Moderate Increased metabolism of Vinorelbine caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [55]
PF-04449913 DMSB068 Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [47]
Mifepristone DMGZQEF Moderate Decreased metabolism of Vinorelbine caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [43]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Vinorelbine caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [56]
MK-8228 DMOB58Q Moderate Decreased metabolism of Vinorelbine caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [57]
Aprepitant DM053KT Moderate Decreased metabolism of Vinorelbine caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [58]
Nefazodone DM4ZS8M Major Decreased clearance of Vinorelbine due to the transporter inhibition by Nefazodone. Depression [6A70-6A7Z] [49]
Griseofulvin DMK54YG Moderate Increased metabolism of Vinorelbine caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [55]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Vinorelbine caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [59]
Cenobamate DMGOVHA Moderate Increased metabolism of Vinorelbine caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [60]
Stiripentol DMMSDOY Moderate Decreased metabolism of Vinorelbine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Fosphenytoin DMOX3LB Moderate Accelerated clearance of Vinorelbine due to the transporter induction by Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [62]
Phenobarbital DMXZOCG Moderate Increased metabolism of Vinorelbine caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Carbamazepine DMZOLBI Moderate Increased metabolism of Vinorelbine caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Tazemetostat DMWP1BH Moderate Increased metabolism of Vinorelbine caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [63]
Itraconazole DMCR1MV Major Decreased clearance of Vinorelbine due to the transporter inhibition by Itraconazole. Fungal infection [1F29-1F2F] [49]
Miconazole DMPMYE8 Moderate Decreased metabolism of Vinorelbine caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [64]
Ketoconazole DMPZI3Q Major Decreased clearance of Vinorelbine due to the transporter inhibition by Ketoconazole. Fungal infection [1F29-1F2F] [49]
Boceprevir DMBSHMF Major Decreased metabolism of Vinorelbine caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [49]
Telaprevir DMMRV29 Major Decreased metabolism of Vinorelbine caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [49]
Rifampin DMA8J1G Moderate Increased metabolism of Vinorelbine caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [55]
Rifapentine DMCHV4I Moderate Increased metabolism of Vinorelbine caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [55]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Vinorelbine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [65]
Delavirdine DM3NF5G Major Decreased metabolism of Vinorelbine caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Vinorelbine caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Cobicistat DM6L4H2 Major Decreased metabolism of Vinorelbine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Efavirenz DMC0GSJ Moderate Increased metabolism of Vinorelbine caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Saquinavir DMG814N Major Decreased metabolism of Vinorelbine caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Etravirine DMGV8QU Moderate Increased metabolism of Vinorelbine caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Vinorelbine and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [68]
Amprenavir DMLMXE0 Major Decreased metabolism of Vinorelbine caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Darunavir DMN3GCH Moderate Decreased metabolism of Vinorelbine caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [69]
Atazanavir DMSYRBX Major Decreased metabolism of Vinorelbine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Ritonavir DMU764S Major Decreased metabolism of Vinorelbine caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Vinorelbine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [70]
BMS-201038 DMQTAGO Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [71]
Conivaptan DM1V329 Major Decreased metabolism of Vinorelbine caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [49]
Tolvaptan DMIWFRL Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [43]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Vinorelbine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [72]
Amobarbital DM0GQ8N Moderate Increased metabolism of Vinorelbine caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [55]
Glycerol phenylbutyrate DMDGRQO Moderate Increased metabolism of Vinorelbine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme. Liver disease [DB90-DB9Z] [47]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Denosumab. Low bone mass disorder [FB83] [73]
Crizotinib DM4F29C Moderate Decreased metabolism of Vinorelbine caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [74]
Brigatinib DM7W94S Moderate Increased metabolism of Vinorelbine caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [75]
Ceritinib DMB920Z Major Decreased metabolism of Vinorelbine caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [49]
PF-06463922 DMKM7EW Moderate Increased metabolism of Vinorelbine caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [76]
Osimertinib DMRJLAT Moderate Increased metabolism of Vinorelbine caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [47]
Capmatinib DMYCXKL Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [77]
Selpercatinib DMZR15V Moderate Decreased metabolism of Vinorelbine caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [47]
Idelalisib DM602WT Major Decreased metabolism of Vinorelbine caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [49]
IPI-145 DMWA24P Moderate Decreased metabolism of Vinorelbine caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [78]
Blinatumomab DMGECIJ Moderate Decreased metabolism of Vinorelbine caused by Blinatumomab mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [79]
LGX818 DMNQXV8 Moderate Increased metabolism of Vinorelbine caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [80]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Vinorelbine caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [47]
Lasmiditan DMXLVDT Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by Lasmiditan. Migraine [8A80] [81]
Exjade DMHPRWG Moderate Decreased metabolism of Vinorelbine caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [82]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Vinorelbine and Thalidomide. Multiple myeloma [2A83] [83]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Tecfidera. Multiple sclerosis [8A40] [84]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Vinorelbine and Siponimod. Multiple sclerosis [8A40] [43]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Vinorelbine and Fingolimod. Multiple sclerosis [8A40] [85]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Ocrelizumab. Multiple sclerosis [8A40] [86]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Vinorelbine and Ozanimod. Multiple sclerosis [8A40] [47]
Rifabutin DM1YBHK Moderate Accelerated clearance of Vinorelbine due to the transporter induction by Rifabutin. Mycobacterium infection [1B10-1B21] [55]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Vinorelbine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Nilotinib DM7HXWT Moderate Decreased metabolism of Vinorelbine caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [87]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Vinorelbine and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [88]
Modafinil DMYILBE Minor Increased metabolism of Vinorelbine caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [44]
Rolapitant DM8XP26 Moderate Decreased clearance of Vinorelbine due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [89]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Vinorelbine caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [90]
Abametapir DM2RX0I Moderate Decreased metabolism of Vinorelbine caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [91]
Lefamulin DME6G97 Moderate Decreased metabolism of Vinorelbine caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [92]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Vinorelbine caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [49]
Enzalutamide DMGL19D Moderate Increased metabolism of Vinorelbine caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [93]
Ustekinumab DMHTYK3 Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Ustekinumab. Psoriasis [EA90] [47]
Tildrakizumab DMLW9HG Moderate Additive myelosuppressive effects by the combination of Vinorelbine and Tildrakizumab. Psoriasis [EA90] [47]
Risankizumab DMM32GT Moderate Additive myelosuppressive effects by the combination of Vinorelbine and Risankizumab. Psoriasis [EA90] [47]
Ixekizumab DMXW92T Moderate Additive myelosuppressive effects by the combination of Vinorelbine and Ixekizumab. Psoriasis [EA90] [47]
Bosentan DMIOGBU Moderate Increased metabolism of Vinorelbine caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [94]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Vinorelbine and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [95]
Gatifloxacin DMSL679 Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [50]
Tocilizumab DM7J6OR Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Tocilizumab. Rheumatoid arthritis [FA20] [47]
Canakinumab DM8HLO5 Moderate Additive myelosuppressive effects by the combination of Vinorelbine and Canakinumab. Rheumatoid arthritis [FA20] [47]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Rilonacept. Rheumatoid arthritis [FA20] [47]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Vinorelbine and Golimumab. Rheumatoid arthritis [FA20] [96]
Dexamethasone DMMWZET Moderate Increased metabolism of Vinorelbine caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [55]
Sarilumab DMOGNXY Moderate Additive immunosuppressive effects by the combination of Vinorelbine and Sarilumab. Rheumatoid arthritis [FA20] [47]
Leflunomide DMR8ONJ Major Additive myelosuppressive effects by the combination of Vinorelbine and Leflunomide. Rheumatoid arthritis [FA20] [70]
Fentanyl DM8WAHT Moderate Decreased metabolism of Vinorelbine caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [97]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Vinorelbine when combined with Anthrax vaccine. Sepsis [1G40-1G41] [98]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Vinorelbine caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [99]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Vinorelbine caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [47]
Pitolisant DM8RFNJ Moderate Increased metabolism of Vinorelbine caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [47]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Vinorelbine caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [100]
Brilinta DMBR01X Moderate Decreased metabolism of Vinorelbine caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [47]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Vinorelbine and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [95]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Vinorelbine and Azathioprine. Transplant rejection [NE84] [43]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Vinorelbine and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [95]
Cinoxacin DM4EWNS Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Cinoxacin. Urinary tract infection [GC08] [50]
Nalidixic acid DMRM0JV Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Nalidixic acid. Urinary tract infection [GC08] [50]
Enoxacin DMYTE6L Minor Decreased absorption of Vinorelbine due to intestinal mucosa variation caused by Enoxacin. Urinary tract infection [GC08] [50]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Vinorelbine and Ganciclovir. Virus infection [1A24-1D9Z] [43]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Vinorelbine and Valganciclovir. Virus infection [1A24-1D9Z] [43]
⏷ Show the Full List of 129 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7105).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Vinorelbine Tartrate
6 The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol. 1994 Oct;21(5 Suppl 10):21-7.
7 Metabolism pathway of vinorelbine (Navelbine?) in human: Characterisation of the metabolites by HPLCCMS/MS
8 Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
9 Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.
10 Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine. Fundam Clin Pharmacol. 2005 Oct;19(5):545-53.
11 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
12 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
22 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
23 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
24 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
25 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
26 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
27 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
28 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
29 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
30 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
31 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
32 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
33 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
34 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
35 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
36 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
37 Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
38 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
39 Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
40 Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
41 2011 Pipeline of ZioPharm.
42 Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res. 2006 May-Jun;26(3A):1973-81.
43 Cerner Multum, Inc. "Australian Product Information.".
44 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
45 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
46 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
47 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
48 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
49 Antoniou T, Tseng AL "Interactions between antiretrovirals and antineoplastic drug therapy." Clin Pharmacokinet 44 (2005): 111-145. [PMID: 15656694]
50 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
51 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
52 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
53 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
54 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
55 Product Information. Marqibo (vinCRIStine liposome). Talon Therapeutics Inc, South San Francisco,, CA.
56 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
57 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
58 Charasson V, Haaz MC, Robert J "Determination of Drug Interactions Occurring with the Metabolic Pathways of Irinotecan." Drug Metab Dispos 30 (2002): 731-733. [PMID: 12019202]
59 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
61 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
62 Bollini P, Riva R, Albani F, Ida et al "Decreased phenytoin level during antineoplastic therapy: a case report." Epilepsia 24 (1983): 75-8. [PMID: 6822234]
63 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
64 Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
65 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
66 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
67 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
68 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
69 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
70 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
71 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
72 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
73 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
74 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
75 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
76 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
77 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
78 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
79 Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
80 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
81 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
82 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
83 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
84 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
85 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
87 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
88 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
89 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
90 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
91 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
92 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
93 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
94 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
95 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
96 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
97 Labroo RB, Paine MF, Thummel KE, Kharasch ED "Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implicaitons for interindividual variability in disposition, efficacy, and drug interactions." Drug Metab Dispos 25 (1997): 1072-80. [PMID: 9311623]
98 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
99 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
100 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.